SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer

Siegel, 2021, Cancer Statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl. J. Med., 367, 1187, 10.1056/NEJMoa1207506 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N. Engl. J. Med., 371, 424, 10.1056/NEJMoa1405095 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med., 364, 1995, 10.1056/NEJMoa1014618 Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J. Clin. Oncol., 26, 242, 10.1200/JCO.2007.12.4008 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Rathkopf, 2017, Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone, Clin. Cancer Res., 23, 3544, 10.1158/1078-0432.CCR-16-2509 Fizazi, 2019, Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer, N. Engl. J. Med., 380, 1235, 10.1056/NEJMoa1815671 Rice, 2019, Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer, Front. Oncol., 9, 801, 10.3389/fonc.2019.00801 Batovska, 2010, Trends in utilization of the pharmacological potential of chalcones, Curr. Clin. Pharmacol., 5, 1, 10.2174/157488410790410579 Dimmock, 1999, Bioactivities of chalcones, Curr. Med. Chem., 6, 1125, 10.2174/0929867306666220401182509 Kontogiorgis, 2005, Synthesis and antiinflammatory activity of coumarin derivatives, J. Med. Chem., 48, 6400, 10.1021/jm0580149 Going, 2018, Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer, J. Proteome Res., 17, 3574, 10.1021/acs.jproteome.8b00636 Zhang, 2017, A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells, Sci. Rep., 7, 9873, 10.1038/s41598-017-10400-3 Szliszka, 2009, Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells, Int. J. Mol. Sci., 11, 1, 10.3390/ijms11010001 Kim, 2012, Methoxychalcone inhibitors of androgen receptor translocation and function, Bioorg. Med. Chem. Lett., 22, 2105, 10.1016/j.bmcl.2011.12.141 Denmeade, 2002, A history of prostate cancer treatment, Nat. Rev. Cancer, 2, 389, 10.1038/nrc801 Knudsen, 2011, Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer, Expert Rev. Endocrinol. Metab., 6, 483, 10.1586/eem.11.33 Moses, 2018, Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer, Cancer Res., 78, 4022, 10.1158/0008-5472.CAN-17-3728 Nguyen, 2017, LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics, Prostate, 77, 654, 10.1002/pros.23313 Young, 2013, Establishment and serial passage of cell cultures derived from LuCaP xenografts, Prostate, 73, 1251, 10.1002/pros.22610 Saar, 2014, Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype, Cancer Lett., 351, 272, 10.1016/j.canlet.2014.06.014 Valta, 2016, Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer, Clin. Exp. Metastasis, 33, 325, 10.1007/s10585-016-9781-2 Rice, 2019, Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies, Mol. Cancer Ther., 18, 1230, 10.1158/1535-7163.MCT-18-0804 Hsu, 2020, Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1, Proc. Natl. Acad. Sci. USA, 117, 2032, 10.1073/pnas.1905384117 Maund, 2014, Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate, Lab. Invest., 94, 208, 10.1038/labinvest.2013.141 Savitski, 2014, Tracking cancer drugs in living cells by thermal profiling of the proteome, Science, 346, 1255784, 10.1126/science.1255784 Tailor, 2021, Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer, Cell Chem. Biol., 28, 1206, 10.1016/j.chembiol.2021.02.014 Bernstein, 1998, Crystal structures of substrates and products bound to the phosphoglycerate kinase active site reveal the catalytic mechanism, Biochemistry, 37, 4429, 10.1021/bi9724117 Banerjee, 2017, Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids, Proc. Natl. Acad. Sci. USA, 114, 3334, 10.1073/pnas.1700677114 Rajeshkumar, 2015, Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function, Cancer Res., 75, 3355, 10.1158/0008-5472.CAN-15-0108 Bok, 2019, The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized 13C MRSI, Cancers (Basel), 11, 257, 10.3390/cancers11020257 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Pavlova, 2016, The Emerging Hallmarks of Cancer Metabolism, Cell Metab., 23, 27, 10.1016/j.cmet.2015.12.006 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Choi, 2018, Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer, Cancer Med., 7, 3385, 10.1002/cam4.1587 Eidelman, 2017, The Metabolic Phenotype of Prostate Cancer, Front. Oncol., 7, 131, 10.3389/fonc.2017.00131 Giunchi, 2019, The Metabolic Landscape of Prostate Cancer, Eur. Urol. Oncol., 2, 28, 10.1016/j.euo.2018.06.010 Sriram, 2020, Elevated Tumor Lactate and Efflux in High-grade Prostate Cancer demonstrated by Hyperpolarized 13C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures, Cancers (Basel), 12, 537, 10.3390/cancers12030537 Xiao, 2018, GLUT1 regulates cell glycolysis and proliferation in prostate cancer, Prostate, 78, 86, 10.1002/pros.23448 Akins, 2018, Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer, Curr. Top. Med. Chem., 18, 494, 10.2174/1568026618666180523111351 Dai, 2015, By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice, Oncotarget, 6, 13703, 10.18632/oncotarget.3800 Singh, 2018, Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate, Cancer Prev. Res. (Phila.), 11, 337, 10.1158/1940-6207.CAPR-17-0389 Pollyea, 2019, Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia, Leukemia, 33, 2575, 10.1038/s41375-019-0472-2 Mullard, 2017, FDA approves first-in-class cancer metabolism drug, Nat. Rev. Drug Discov., 16, 593, 10.1038/nrd.2017.196 Xiang, 2019, Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization, Cell Death Dis., 10, 40, 10.1038/s41419-018-1291-5 Xu, 2017, HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma, Mol. Cancer, 16, 178, 10.1186/s12943-017-0748-y Wagner, 2013, A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas, Clin. Cancer Res., 19, 6020, 10.1158/1078-0432.CCR-13-0953 Trepel, 2010, Targeting the dynamic HSP90 complex in cancer, Nat. Rev. Cancer, 10, 537, 10.1038/nrc2887 Oh, 2011, Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer, Urology, 78, 626, 10.1016/j.urology.2011.04.041 Thakur, 2016, A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study, Invest. New Drugs, 34, 112, 10.1007/s10637-015-0307-6 Tusher, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc. Natl. Acad. Sci. USA, 98, 10.1073/pnas.091062498 Navarro, 2014, General statistical framework for quantitative proteomics by stable isotope labeling, J. Proteome Res., 13, 1234, 10.1021/pr4006958 Tyanova, 2016, The Perseus computational platform for comprehensive analysis of (prote)omics data, Nat. Methods, 13, 731, 10.1038/nmeth.3901 Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 Echeverría, 2011, An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine, PLoS ONE, 6, e26044, 10.1371/journal.pone.0026044 Perez-Riverol, 2019, The PRIDE database and related tools and resources in 2019: improving support for quantification data, Nucleic Acids Res., 47, D442, 10.1093/nar/gky1106 Eberlin, 2011, Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging, Biochim. Biophys. Acta, 1811, 946, 10.1016/j.bbalip.2011.05.006 Vijayalakshmi, 2020, Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging, Int. J. Cancer, 147, 256, 10.1002/ijc.32843